February 25, 2021
Business News

Mydecine Innovations Group Files Preliminary Prospectus in Connection with Bought Deal Offering of Units


DENVER–()–Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, is pleased to announce that, in connection with its bought deal offering (the “Offering”) previously announced on January 14, 2021, it has filed a preliminary short form prospectus (the “Preliminary Prospectus”) with the securities commissions or similar authorities in each province of Canada, other than Quebéc, and entered into an underwriting agreement with Canaccord Genuity Corp. (the “Underwriter”) dated January 20, 2021 (the…



Click here to view the original article.

Related Posts

You might also like ...

Charles River Associates (CRA) Expands Geographic Presence
AON Splash Image
Wellington Management Expands Private Investing Capabilities with New Climate-Focused Senior Investors
Genus plc Reports Interim First Half 2021 Fiscal Year Results